Yake Biotechnology Ltd.
50
24
24
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 50 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (50)
Clinical Study of Anti-CLL1-CD33-NKG2D Bicephali CAR-T for Relapsed/Refractory Acute Myeloid Leukemia
Role: collaborator
A Multicenter Study of CAR-T Cells in Primary Ph+All
Role: collaborator
Donor Derived CD117 CAR-T Cells in the Treatment of R/R Acute Myeloid Leukemia
Role: collaborator
CD7 CAR-T Bridging to alloHSCT for R/R CD7+Malignant Hematologic Diseases
Role: collaborator
Evaluate the Safety and Efficacy of CAR-T Cells in the Treatment of R/R Neuromyelitis Optica
Role: collaborator
Safety and Efficacy of CAR-T Cell Therapy for Relapsed/refractory Neuroblastoma and Desmoplastic Small Round Cell Tumors: a Single-arm, Open-label Trial.
Role: collaborator
Donor Derived CD19 CAR-T Cells in the Treatment of R/R B-cell Acute Lymphoblastic Leukemia
Role: collaborator
CD7 CAR-T Cell Sequential Allo-HSCT for Non-malignant Blood and Immune System Diseases
Role: collaborator
CD19/BCMA CAR-T Cell Therapy for Refractory/Relapsed Lupus Nephritis
Role: collaborator
Clinical Study on the Safety and Efficacy of CD7 CAR-T Cell Sequential Allo-HSCT and Kidney Transplantation in the Treatment of SIOD
Role: collaborator
A Clinical Study to Explore the Safety and Efficacy of CD33 CAR-T Cell in Relapsed/Refractory Acute Myeloid Leukemia
Role: collaborator
A Study on the Efficacy of GD2-CAR T Cells in the Treatment of Neuroblastoma
Role: collaborator
Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph+ B-ALL
Role: collaborator
Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-ALL
Role: collaborator
CD7 CAR-T Bridging to alloHSCT for Severe Aplastic Anemia
Role: collaborator
Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-lymphoma
Role: collaborator
CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL
Role: collaborator
CD19-BAFF CAR-T Cells Therapy for Patients With Autoimmune Diseases
Role: collaborator
CD19 CAR-T Therapy for Patients With B-cell Non-Hodgkin's Lymphoma
Role: collaborator
Clinical Trial for the Safety and Efficacy of Anti-CD7 CAR-T Cell Therapy for Patients With Relapsed or Refractory CD7 Positive Hematological Malignancy
Role: collaborator